Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)
NCT ID: NCT04453280
Last Updated: 2020-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
695 participants
OBSERVATIONAL
2020-05-18
2020-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2
NCT04655521
Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre
NCT04446338
COVID-19 Antibodies Among Healthcare Workers
NCT04425889
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
NCT04520880
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The SARS-CoV-2-CZ-Immunity study is aiming at the determination of the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 - Prague and Central Bohemian Region
A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
Quantitative analysis of anti-SARS-CoV-2-antibodies
Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
SARS-CoV-2 diagnostic rapid test
The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
Cohort 2 - South Moravian Region
A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
Quantitative analysis of anti-SARS-CoV-2-antibodies
Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quantitative analysis of anti-SARS-CoV-2-antibodies
Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
SARS-CoV-2 diagnostic rapid test
The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* residing in Prague, Central Bohemian Region or South Moravian Region
* demographic criteria: persons aged 8-17 and persons aged 18 and more
* clinical criteria: (i) diagnosis of COVID-19 confirmed by PCR (ii) cured patients: clearance of SARS-CoV-2 viral RNA demonstrated by two consecutive negative RT-PCR results (iii) without acute health problems
8 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Czech Republic
OTHER_GOV
Masaryk University
OTHER
Institute for Clinical and Experimental Medicine
OTHER_GOV
Brno University Hospital
OTHER
St. Anne's University Hospital Brno, Czech Republic
OTHER
Masaryk Memorial Cancer Institute
OTHER
Regional Public Health Office of the South Moravian Region based in Brno, Czech Republic
UNKNOWN
Public Health Office of the Capital City of Prague, Czech Republic
UNKNOWN
Regional Public Health Office of the Central Bohemian Region based in Prague, Czech Republic
UNKNOWN
Institute of Health Information and Statistics of the Czech Republic
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roman Prymula, Prof.
Role: PRINCIPAL_INVESTIGATOR
Ministry of Health, Czech Republic
Jarmila Rážová, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ministry of Health, Czech Republic
Ladislav Dušek, Prof.
Role: PRINCIPAL_INVESTIGATOR
Institute of Health Information and Statistics of the Czech Republic
Dalibor Valík, Prof.
Role: PRINCIPAL_INVESTIGATOR
Masaryk Memorial Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Health Information and Statistics of the Czech Republic
Prague, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UZIS 2020/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.